Zeranol (Ralgro)

Zeranol is a resorcyclic acid lactone compound with estrogenic properties that serves as a growth promotant in beef cattle and sheep in jurisdictions where hormonal implants are legally permitted. Originally derived from zearalenone, a mycotoxin produced by Fusarium fungi, zeranol was developed and purified as a safe and effective growth-promoting agent for food-producing animals. Unlike steroidal estrogens, zeranol provides estrogenic activity through a non-steroidal chemical structure, which has contributed to its widespread acceptance and relatively favorable safety profile in livestock production applications.

The mechanism of action of zeranol involves binding to estrogen receptors in target tissues throughout the body, triggering a cascade of anabolic effects that enhance protein synthesis and growth. When zeranol binds to estrogen receptors in the hypothalamus and pituitary, it stimulates the release of growth hormone and insulin-like growth factor-1, which are primary mediators of skeletal and muscle growth. Additionally, zeranol influences nutrient partitioning, directing metabolic resources toward lean tissue accretion rather than fat deposition. This hormonal stimulation creates a more favorable growth environment that allows animals to utilize feed nutrients more efficiently while achieving improved rates of gain.

Zeranol for livestock use is available as subcutaneous implant pellets designed for placement in the ear, marketed primarily under the Ralgro brand name. The standard Ralgro implant contains 36 mg of zeranol formulated for approximately 100-day payout period, while Ralgro Magnum contains 72 mg for extended duration of approximately 120 days. The implant pellets are designed to dissolve gradually in the subcutaneous tissue, providing sustained release of the active compound throughout the payout period. This controlled-release mechanism maintains relatively stable hormone levels, avoiding the peaks and troughs associated with other delivery routes and contributing to the product's favorable safety profile.

The regulatory status of zeranol reflects its established safety record and decades of commercial use in livestock production. In the United States, zeranol is FDA-approved for use in beef cattle and sheep without restriction on animal sex or production stage, making it one of the most versatile growth promotant options available. The over-the-counter status of zeranol implants simplifies access for producers, though responsible use practices should still be followed. As with other hormonal growth promotants, zeranol is prohibited in the European Union and certain export markets, requiring producers to verify market specifications before implementing implant programs in cattle or sheep destined for these destinations.

The primary labeled indication for zeranol implants is growth promotion across a broad range of cattle and sheep production systems, from nursing calves through feedlot finishing. In beef cattle, zeranol improves average daily gain by 10 to 15 percent while enhancing feed conversion efficiency, reducing the amount of feed required per unit of gain. The relatively mild estrogenic activity of zeranol makes it particularly suitable for young calves and situations where more potent implants might produce unwanted effects. The economic benefits of zeranol use accumulate throughout the production chain, as improved growth rates and feed efficiency translate directly to reduced cost of production.

Species-specific applications of zeranol span both cattle and sheep, making it unique among growth promotant implants in its approved multi-species indication. In cattle, zeranol is approved for use in suckling calves, weaned calves, growing cattle, and feedlot finishing cattle regardless of sex. This versatility allows producers to implement consistent implant programs from birth through harvest using a single compound family. In sheep, zeranol is approved for use in lambs, providing growth promotion benefits in lamb finishing operations. The ability to use zeranol across multiple species and production stages simplifies inventory management and provides flexibility in production system design.

Zeranol serves primarily as a growth promotant and efficiency enhancer rather than a therapeutic agent, with its applications centered on improving production economics rather than treating disease. The mild estrogenic activity of zeranol makes it an appropriate choice as a first implant for young calves where more aggressive compounds might be inappropriate. In stocker operations and backgrounding programs, zeranol provides growth benefits during the growing phase while cattle are consuming forage-based diets. For feedlot finishing, zeranol may be used alone as a mild implant option or as the foundation layer in more aggressive reimplantation protocols that progress to combination products containing androgens.

Production applications for zeranol span the entire beef cattle production cycle from pre-weaning through harvest, with specific protocols optimized for each phase. Pre-weaning implantation of suckling calves with zeranol has been demonstrated to improve weaning weights and provide lasting benefits that extend into subsequent production phases. Stocker and backgrounding programs benefit from zeranol's growth enhancement while cattle are developing frame and capacity on forage-based diets. Feedlot finishing programs may utilize zeranol as an entry implant with subsequent progression to more potent products, or may use zeranol alone in cattle destined for programs with implant potency restrictions. In sheep, zeranol is used during lamb finishing to improve growth rates and feed efficiency.

Extra-label applications of zeranol are not specifically prohibited under the general provisions allowing veterinary discretion for extra-label drug use, though the broad labeled approvals for this product make extra-label use rarely necessary. The approval of zeranol for use in cattle and sheep of all ages and sexes covers most production scenarios. Any extra-label use would require establishment of appropriate withdrawal periods and compliance with food safety requirements. The over-the-counter status of zeranol does not change the requirements for responsible use and attention to withdrawal period compliance when marketing animals for slaughter.

Dosing of zeranol is standardized within the available implant formulations, with product selection based on the desired duration of effect rather than adjusting dose for animal size or weight. The standard Ralgro implant contains 36 mg of zeranol in pellet form, designed to provide effective growth stimulation for approximately 100 days. Ralgro Magnum contains 72 mg of zeranol in an extended-release formulation designed for approximately 120-day payout. In sheep, the Ralgro implant containing 12 mg zeranol is used for lambs. The fixed dosing of implant products simplifies administration and ensures consistent delivery of the active compound across animals of varying sizes.

The route of administration for zeranol implants is subcutaneous placement in the ear, consistent with other growth promotant implants. In cattle, implants are placed in the middle third of the posterior surface of the ear, between the skin and cartilage. Proper placement ensures optimal absorption and eliminates the possibility of implant pellets entering edible tissues, as ears are discarded at slaughter. In sheep, the implant is similarly placed subcutaneously in the ear using appropriate-sized equipment designed for ovine administration. The ear implant site provides consistent absorption across species while ensuring food safety through physical exclusion from the food supply.

Treatment duration corresponds to the payout period of the selected zeranol product, with reimplantation indicated when continuous growth stimulation is desired beyond the initial implant's effective duration. Standard Ralgro implants maintain effective zeranol levels for approximately 100 days, after which reimplantation may be performed if cattle remain in production. Ralgro Magnum provides extended duration of approximately 120 days, reducing the number of processing events required for cattle on longer feeding programs. For cattle on extended production cycles, strategic reimplantation at appropriate intervals maintains continuous growth benefits throughout the production period.

Proper administration technique for zeranol implants follows the same principles established for all ear implant products. The implant gun should be clean and in good working order with a sharp needle to minimize tissue trauma. The animal should be adequately restrained with the ear accessible and visible. The needle is inserted subcutaneously at the tip of the ear and advanced toward the head, with pellets deposited in a line between the skin and cartilage as the needle is withdrawn. Palpation of the implant site after placement verifies that pellets are properly positioned. In sheep, smaller equipment appropriate for the species is used, but the technique remains consistent with cattle implantation.

Mass administration of zeranol implants is common practice in cow-calf operations at branding or weaning time and in feedlot operations during processing. Efficient implant administration requires proper chute setup, adequate restraint, and trained personnel to ensure consistent technique. In large operations, quality control measures should include periodic verification of proper implant placement and monitoring for complications. Record-keeping systems should document implant dates, products used, and animal identification to enable compliance verification and traceability throughout the production chain.

Withdrawal times for zeranol implants must be observed to ensure compliance with food safety standards and prevent violative residues. The withdrawal period for standard Ralgro implants in cattle is 65 days before slaughter, while Ralgro Magnum requires no withdrawal period when used according to label directions. In sheep, the withdrawal period is 40 days before slaughter. These withdrawal periods assume proper implant placement in the ear. Implants placed outside the approved ear location can result in violative residues regardless of time elapsed since implantation. Accurate records documenting implant dates and products are essential for verifying withdrawal compliance before cattle or sheep are marketed.

Zeranol implants demonstrate an excellent general tolerability profile across cattle and sheep, with the compound's relatively mild estrogenic activity producing fewer side effects compared to more potent growth promotants. Decades of commercial use have established zeranol as one of the most well-tolerated implant products available, with serious adverse effects being uncommon when the product is used according to label directions. The controlled-release implant delivery mechanism contributes to the favorable side effect profile by maintaining steady hormone levels throughout the payout period without the fluctuations associated with other delivery routes.

Common side effects observed in cattle receiving zeranol implants are generally mild and related to the expected physiological effects of estrogenic stimulation. Some increase in mounting behavior may be observed, though this effect is typically less pronounced with zeranol compared to androgenic implants or more potent estrogen combinations. Elevated tailhead, a slight raising of the region at the base of the tail, may develop as a result of estrogen-induced relaxation of pelvic ligaments and is considered a cosmetic effect without welfare implications. Teat development in steers, if it occurs, is generally mild with zeranol compared to more potent implants and typically resolves after the implant is exhausted.

Injection site reactions with zeranol implants are similar to those observed with other ear implant products. Minor local tissue response at the implantation site is normal and typically resolves without intervention. Improper implant technique can result in complications including abscess formation, pellet bunching that impairs hormone release, or cartilage damage from needle placement in incorrect tissue planes. Implant site infections may occur, particularly if contaminated equipment is used or if implants are placed through damaged or infected ear tissue. Regular monitoring of implant sites enables early identification of problems requiring management attention.

Serious adverse effects from zeranol implants are uncommon, reflecting both the compound's mild estrogenic activity and its established safety record. Vaginal and rectal prolapse, which can occur with more potent implants particularly in aggressive reimplantation protocols, is rarely associated with zeranol-only implant programs. However, risk may increase when zeranol is combined with more potent compounds or when used in animals predisposed to prolapse. Reproductive effects in breeding animals represent the primary serious concern, which is managed through the general recommendation to avoid implanting animals intended for breeding purposes even though zeranol is technically approved for use in all cattle.

Species-specific considerations for zeranol tolerability reflect the product's approval for use in both cattle and sheep. In cattle, the favorable tolerability profile is consistent across ages and sexes, supporting the broad labeled indications for this compound. In sheep, zeranol is generally well-tolerated when administered according to label directions, though producers should ensure appropriate implant equipment is used to prevent excessive tissue trauma in the smaller ear structure. The withdrawal periods established for each species should be rigorously observed to ensure food safety and compliance with regulatory requirements.

Species restrictions for zeranol are less extensive than for many other growth promotant implants, as the product carries FDA approval for use in both beef cattle and sheep. However, use in dairy cattle is not approved, and zeranol must not be administered to cattle or calves producing milk for human consumption. Use in other livestock species including swine and poultry is not approved, and the estrogenic effects of zeranol in non-approved species could produce unpredictable results. The multi-species approval for cattle and sheep provides production flexibility, but producers must ensure that implant use aligns with the specific regulatory framework governing their animals.

Production stage restrictions for zeranol are minimal compared to other growth implants, as the product is approved for use in cattle and sheep regardless of sex or production stage. Nevertheless, practical considerations suggest avoiding zeranol implantation in animals intended for breeding purposes. While not explicitly contraindicated for breeding animals, the estrogenic effects of zeranol can potentially disrupt normal reproductive function, particularly in developing heifers where exposure during sexual maturation could influence future fertility. Producers planning to retain females for breeding should exclude these animals from implant programs as a precautionary measure even though such use would be technically permitted under the label.

Age and weight restrictions for zeranol are notably absent from the product labeling, making it one of the most versatile growth promotant options available. Zeranol is approved for use in suckling calves as young as birth, supporting pre-weaning implantation programs that have been demonstrated to improve weaning weights. There are no minimum weight requirements for cattle, though practical considerations suggest that very small calves may be difficult to implant accurately with standard equipment. In sheep, the implant is approved for use in lambs without specific age or weight restrictions, though appropriate equipment should be selected to accommodate the smaller anatomy.

Disease state contraindications for zeranol implants center primarily on conditions affecting the implant site or that would compromise the animal's ability to respond to growth stimulation. Cattle or sheep with significant ear pathology including infections, injuries, or tissue damage from previous implant complications should not receive implants until these conditions resolve. Animals that are acutely ill, severely stressed, or experiencing significant disease challenges may not respond optimally to growth promotants and may benefit from delayed implantation until health status improves. The relatively mild nature of zeranol means that fewer absolute contraindications exist compared to more potent products, but responsible use still requires attention to individual animal condition.

Important drug class interactions with zeranol primarily involve considerations around combining this estrogenic compound with other growth-promoting technologies. Zeranol is frequently used as the first implant in programs that progress to more potent products containing androgens such as testosterone or trenbolone acetate. The sequential use of zeranol followed by combination implants represents a standard approach in feedlot operations seeking to optimize growth throughout extended feeding periods. When zeranol is combined with androgenic implants in reimplantation programs, the total hormonal load should be considered to avoid excessive stimulation that could increase the risk of adverse effects.

Ionophore interactions are not a concern with zeranol implants, as these technologies work through entirely different physiological mechanisms without pharmacological interaction. Ionophore feed additives including monensin and lasalocid improve feed efficiency through modification of rumen fermentation, while zeranol acts through systemic estrogen receptor activation. The two technologies can be safely combined and are routinely used together in both stocker and feedlot operations where maximum efficiency is desired. The complementary mechanisms of action may result in additive improvements in feed efficiency when both technologies are employed.

Feed additive interactions with zeranol are limited, as the compound's mechanism of action does not directly overlap with most feed additives used in cattle and sheep production. In heifer feeding programs, zeranol implants may be used in conjunction with melengestrol acetate, a progestational feed additive used for estrus suppression and growth promotion. The combination of estrogenic implant with progestational feed additive is generally compatible, though attention to total hormonal effects is warranted. Beta-agonist feed additives including ractopamine can be combined with zeranol implant programs during the finishing phase, with the technologies working through complementary mechanisms to enhance growth and carcass characteristics.

Vaccine interactions with zeranol are not documented as direct pharmacological interactions, though practical considerations apply when implant administration coincides with other processing events. The mild nature of zeranol means that any effects on immune function are likely to be minimal compared to more potent implant products. Processing events where cattle receive implants along with vaccinations and other treatments are common practice, and the combination is generally well-tolerated in healthy cattle. Best practices include ensuring animals are in good health and not experiencing significant stress when implanted, which supports both optimal implant response and effective immune response to vaccines administered concurrently.

Human safety considerations for zeranol reflect the compound's estrogenic activity and the potential for adverse effects from inadvertent exposure. While zeranol is not classified as a controlled substance and presents fewer handling concerns than some other growth promotants, reasonable precautions should still be observed. Gloves should be worn during implant administration to minimize skin contact, and hands should be washed thoroughly after handling implant products. Pregnant women should avoid handling zeranol products as a precaution against potential hormonal effects, though the risk is generally considered lower than with more potent compounds. Care should be taken to avoid needle stick injuries during implantation.

Food safety and residue avoidance are ensured through the ear implant administration route, which physically separates the implant site from edible tissues. Proper implant placement in the subcutaneous tissue of the ear is essential for this safety system to function as designed. Implants placed in locations other than the ear can result in violative tissue residues and carcass condemnation. The established withdrawal periods for zeranol products must be observed, with standard Ralgro requiring 65 days and Ralgro Magnum requiring no withdrawal when used according to label directions. Accurate record-keeping documenting implant dates and animal identification enables verification of withdrawal compliance before marketing.

Environmental considerations for zeranol include proper disposal of unused or damaged implant products and associated materials. While zeranol is not classified as a controlled substance, pharmaceutical waste should still be disposed of responsibly to prevent environmental contamination or access by wildlife. Sharps disposal protocols apply to implant needles, which should be placed in appropriate puncture-resistant containers. Environmental fate studies have examined the behavior of estrogenic compounds including zeranol in agricultural systems, with findings informing best management practices for manure handling in operations using growth implants.

Resistance concerns do not apply to zeranol as they do to antimicrobial agents, but considerations of responsible use apply to growth promotant technologies in terms of maintaining public confidence in food production. Zeranol represents a relatively low-intensity option within the growth promotant category, and its use is generally consistent with programs seeking more moderate implant approaches. Some quality systems and branded beef programs restrict implant use but may allow zeranol-only programs where more potent implants are prohibited, making accurate documentation important for marketing compliance.

Proper use guidelines for zeranol emphasize adherence to label directions and appropriate product selection for the production scenario. While zeranol's favorable safety profile provides flexibility, effective use requires matching reimplantation intervals to product payout periods and ensuring appropriate withdrawal time before slaughter. The mild nature of zeranol makes it suitable as a foundational implant in young cattle or as a standalone option in programs seeking moderate growth enhancement without the intensity of combination products. Record-keeping must accurately document implant dates and products to ensure compliance with withdrawal requirements and enable traceability throughout production.

Storage requirements for zeranol implants specify protection from environmental conditions that could compromise product integrity. Products should be stored at controlled room temperature, protected from excessive heat, light, and moisture. Freezing should be avoided as it may affect the physical structure of implant pellets. Because zeranol is not classified as a controlled substance, storage requirements are less stringent than for products like trenbolone acetate, though reasonable security to prevent loss or misuse is still appropriate. Original packaging should be maintained until use to protect pellets from environmental exposure and physical damage. Products should be inspected before use to verify that pellets are intact and cartridges are undamaged.

Handling of zeranol implants requires attention to maintaining product integrity and preventing contamination. Gloves should be worn during implant administration to minimize handler exposure to the estrogenic compound. Implant cartridges should be visually inspected before loading to verify pellet integrity, as damaged or fragmented pellets can result in erratic hormone release. Implant guns and needles should be maintained in proper working condition, with needles replaced when dull or bent. In field conditions, exposure of unused implants to dust and debris should be minimized by keeping packaging sealed until needed. Any implant products dropped on the ground or otherwise contaminated should be discarded rather than used.

Disposal of zeranol implant products follows standard pharmaceutical waste disposal practices, with less stringent requirements than for controlled substances. Unused, expired, or damaged implants should not be discarded in regular trash where they could be accessed by wildlife or domestic animals. Disposal through veterinary waste collection services or other appropriate channels ensures that products are handled responsibly. Sharps disposal protocols apply to implant needles, which must be placed in appropriate puncture-resistant containers for collection by licensed waste handlers. Empty cartridges and packaging can typically be disposed of as regular waste once the implant pellets have been administered or otherwise properly disposed of.

Species-specific dosing considerations for zeranol reflect the product's approval for use in both cattle and sheep with formulations calibrated for each species. In cattle, the standard 36 mg and 72 mg zeranol formulations are used across all animal types regardless of breed, sex, or production stage, with the mild estrogenic activity providing consistent response across diverse genetics. In sheep, the 12 mg formulation is used for lambs, with the reduced dose reflecting the smaller body size and different metabolic characteristics of ovine compared to bovine species. The fixed dosing within species simplifies administration and ensures consistent delivery across animals of varying sizes.

Breed sensitivities to zeranol have not been extensively documented as a significant concern, reflecting the compound's mild estrogenic activity and favorable tolerability profile across diverse genetics. British breeds including Angus and Hereford respond well to zeranol implantation, as do Continental breeds with higher growth potential. Brahman-influenced cattle and other Bos indicus genetics may show somewhat different response patterns, though zeranol's mild activity means that breed-related concerns are less pronounced than with more potent implants. The versatility of zeranol across breed types supports its use in diverse production systems from purebred operations to commercial crossbred herds.

Production type considerations influence zeranol implant decisions based on end market requirements and program specifications rather than animal response variations. While zeranol is approved for broad use in beef cattle and sheep, dairy cattle are excluded from approved applications. Within beef production, zeranol's mild nature makes it compatible with more quality system requirements than aggressive implant products. Some branded programs or premium marketing channels that restrict implant use may permit zeranol-only programs where combination products containing androgens are prohibited. Producers must verify specific program requirements and maintain accurate documentation to ensure marketing compliance.

Age and weight considerations for zeranol are notably minimal compared to other growth implants, with the product approved for use in suckling calves as well as mature cattle. Pre-weaning implantation with zeranol has been demonstrated to improve weaning weights, supporting calf implant programs in cow-calf operations. The mild estrogenic activity of zeranol makes it particularly appropriate for young calves where more potent implants might produce unwanted effects on development. In stocker and backgrounding programs, zeranol provides consistent growth enhancement during the growing phase. For feedlot finishing, zeranol may serve as an entry implant followed by more potent products, or may be used alone throughout the feeding period in operations preferring milder implant intensity.

Same-class alternatives to zeranol include other estrogenic compounds used for growth promotion in livestock, though zeranol's unique resorcyclic acid lactone structure distinguishes it from steroidal estrogens. Estradiol benzoate and estradiol 17-beta are steroidal estrogens used in various implant products, often in combination with androgenic compounds. These steroidal estrogens provide similar estrogenic activity through the same receptor mechanisms but represent different chemical classes with somewhat different pharmacokinetic properties. The choice between zeranol and steroidal estrogens often depends on specific production goals, combination product availability, and regulatory considerations in different markets.

Different mechanism alternatives for growth promotion include androgenic compounds that promote growth through androgen receptor activation rather than estrogenic pathways. Testosterone and trenbolone acetate represent the primary androgenic growth promotants, available in various implant formulations either alone or in combination with estrogens. These compounds provide more aggressive growth stimulation than zeranol alone but with increased potential for behavioral and physiological side effects. Melengestrol acetate, a progestational compound administered as a feed additive, provides an alternative mechanism for growth promotion and estrus suppression in heifers. Beta-agonist feed additives including ractopamine offer yet another mechanistically distinct approach to enhancing growth and carcass composition.

Combination products incorporating estrogenic compounds with androgens represent the dominant category of growth implants in intensive beef production. Products such as Revalor and Synovex families combine estradiol with trenbolone acetate or testosterone to achieve synergistic growth effects that exceed what either compound class achieves alone. Zeranol is typically used as a standalone product rather than in combination formulations, though it may be incorporated into reimplantation programs that progress from zeranol alone to combination products. The mild nature of zeranol makes it complementary to more aggressive combination products in strategic implant programs designed to optimize growth throughout extended production periods.